Obesity and type-2 diabetes in the elderly

Gerontology

Volumn 49, Issue 3, 2003, Pages 137-145

  Dewan, Shivani ^a   Wilding, John P H ^a  

^a UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

Author keywords

Obesity; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ANTIDIABETIC AGENT; ANTIOBESITY AGENT; FATTY ACID; GLICLAZIDE; INSULIN; LEPTIN; METFORMIN; REPAGLINIDE; RESISTIN; SIBUTRAMINE; SULFONYLUREA DERIVATIVE; TETRAHYDROLIPSTATIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANOREXIA; BODY WEIGHT; CALORIC INTAKE; CLINICAL TRIAL; CONSTIPATION; DIET; DISEASE COURSE; DISEASE PREDISPOSITION; ENVIRONMENTAL FACTOR; FECES COMPOSITION; FECES INCONTINENCE; FLATULENCE; GENETIC RISK; HEALTH HAZARD; HEART RATE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIFESTYLE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITION; OBESITY; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT EDUCATION; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIDE EFFECT; SOCIAL PSYCHOLOGY; VERTIGO; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ADULT; AGED; ANTHROPOMETRY; CONTINENTAL POPULATION GROUPS; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEALTH BEHAVIOR; HUMANS; MALE; MIDDLE AGED; OBESITY; SOCIOECONOMIC FACTORS;

EID: 0037268898     PISSN: 0304324X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000069176     Document Type: Review

References (64)

1. Food and Nutrition Board: Criteria for evaluating weight management programmes; in Thomas PR (ed): Nature and Problem of Obesity. Washington, National Academy Press, 1995, pp 10-11.
2. Ohlson LO, Larsson B, Svardsudd K, et al: The influence of body fat distribution on the incidence of diabetes mellitus. 13.5 years of follow-up of the participants in the study of men born in 1913. Diabetes 1985;34:1055-1058.
3. Després JP: Treatment of obesity: Need to focus on high-risk abdominally obese patients. BMJ 2001;322:716-720.
4. Lean MEJ, Han TS, Seidell JC: Impairment of health and quality of life in people with large waist circumference. Lancet 1998;351:853-856.
5. Chan JM, Rimm EB, Colditz GA, et al: Obesity, fat distribution and weight gain as risk factors for clinical diabetes in men. Diabetes Care 1994;17:961-969.
6. Prescott-Clarke P, Primatesta P: Health Survey for England 1996. London, HMSO, 1998.
7. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL: Increasing prevalence of overweight amongst US adults. The National Health and Nutrition Examination Surveys 1960 to 1991. JAMA 1994;272:205-211.
8. Popkin BM: The nutrition transition in low-income countries - An emerging crisis. Nutr Rev 1994;52:285-298.
9. Elia M: Obesity in the elderly. Obes Res 2001;9(suppl 4):244-248.
10. Jervell J: Type 2 diabetes (NIDDM) can be prevented. IDF Bull 1997;42:1-3.
11. Zimmer P, McCarty D: The NIDDM epidemic: Global estimates and projection - a look into the crystall ball. IDF Bull 1995;40:8-16.
12. Harris MI: Epidemiology of diabetes mellitus among the elderly in the United States. Clin Geriatr Med 1990;6:703-719.
13. King H, Rewers M: Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults. WHO Ad Hoc Diabetes Reporting Group. Diabetes Care 1993;16:157-177.
14. Knowler WC, Bennett PH, Hamman RF, Miller M: Diabetes incidence and prevalence in Pima Indians: A 19-fold greater incidence than in Rochester, Minnesota. Am J Epidemiol 1978;108:497-505.
15. Tuomilehto J, Nissinen A, Kivela SL, Pekkanen J, Kaarsalo E, Wolf E, Aro A, Punsar S, Karvonen MJ: Prevalence of diabetes mellitus in elderly men aged 65-84 years in eastern and western Finland. Diabetologia 1986;29:611-615.
16. Harris MI, Hayden WC, Knowler WC, Bennett PH: Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in US population aged 20-74. Diabetes 1987;36:523-534.
17. Wilson PWF, Anderson KM, Kannel B: Epidemiology of diabetes mellitus in the elderly. Am J Med 1986;80(suppl 5A):3-9.
18. Mykkänen L, Laakso M, Uusitupa M, Pyorala K: Prevalence of diabetes and impaired glucose tolerance in elderly subjects and their association with obesity and family history of diabetes. Diabetes Care 1990;13:1099-1105.
19. Cole TJ, Freeman JV, Preece MA: Body mass index reference curves for the UK, 1990. Arch Dis Child 1995;73:25-29.
20. Börjeson M: The aetiology of obesity in children. Acta Paediatr Scand 1976;65:279-287.
21. Bouchard C, Tremblay A, Despres JP, et al: The response to long-term feeding in identical twins. N Engl J Med 1990;322:1477-1482.
22. Heitmann BL, Lissner L: Dietary underreporting by obese individuals - is it specific or non-specific? BMJ 1995;311:986-989.
23. Webb T, Clarke D, Hardy CA, Kilpatrick MW, Corbett J, Dahlitz M: A clinical, cytogenetic, and molecular study of 40 adults with the Prader-Willi syndrome. J Med Genet 1995;32:181-185.
24. Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ, et al: Congenital leptin deficiency is associated with severe early onset obesity in humans. Nature 1997;387:903-908.
25. Yeo GSH, Farooqi IS, Aminian S, Halsall DJ, Stanhope RC, O'Rahilly S: A frameshift mutation in MC4R associated with dominantly inherited human obesity. Nat Genet 1998;20:111-112.
26. Krude H, Beibermann H, Luck W, Horn R, Brabant G, Gruters A: Severe early onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet 1998;19:155-157.
27. Ravussin E: Metabolic differences in the development of obesity. Metabolism 1995;9(suppl 3):12-14.
28. Bennett N, Dodd T, Flatley J, Freeth S, Bolling K: Health Survey for England 1993. London, HMSO, 1995.
29. Feskens EJM, Virtanen SM, Rasanen L, Tuomilehto J, Stengard J, Pekkanen J, Nissinen A, Kromhout D: Dietary factors determining diabetes and impaired glucose tolerance. Diabetes Care 1995;18:1104-1112.
30. Lawton C, Burley V, Wales J, Blundell J: Dietary fat and appetite control in obese subjects: Weak effects on satiation and satiety. Int J Obes 1993;17:409-416.
31. Rissanen A, Heliovaara M, Knekt P, et al: Determinants of weight gain and overweight in adult Finns. Eur J Clin Nutr 1991;45:419-430.
32. Barker DJP: Foetal origins of coronary heart disease. BMJ 1995;311:171-174.
33. Hales CN, Barker DJ: Type 2 (non-insulin dependant) diabetes mellitus: the thrifty phenotype hypothesis. Diabetologia 1992;35:595-601.
34. Kopelman PG: Obesity as a medical problem. Nature 2000;404:635-643.
35. Peiris AN, Struve MS, Mueller RA, et al: Glucose metabolism in obesity: Influence of body fat distribution. J Clin Endocrinol Metab 1998;67:760-767.
36. Hotamisligil GS, Budavari A, Murray D, Speigelman BM: Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. J Clin Invest 1994;94:1543-1549.
37. Yamauchi T, Kamon J, Waki H, Tearauchi Y, et al: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7:941-946.
38. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA: Hypoadinectemia in obesity and type 2 diabetes: Close association with insulin resistance. J Clin Endocrinol Metab 2001;86:1930-1935.
39. Holcomb IM, Kabakoff RC, Chan B, Baker TW, Gurney A, Henzel W, Nelson C, Lowman HB, Wright BD, Skelton NJ, Frantz GD, Tumas DB, Peale FV Jr, Shelton DL, Hebert CC: FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. EMBO J 2000;19: 4055.
40. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA: The hormone resistin links obesity to diabetes. Nature 2001;409:307-312.
41. Meneilly GS, Elliot T: Metabolic alterations in middle aged and elderly obese patients with type 2 diabetes. Diabetes Care 1999;22:112-118.
42. Arner P, Pollare T, Lithell H: Different aetiologies of type 2 (non-insulin dependent) diabetes mellitus in obese and non-obese subjects. Diabetologia 1991;34:483-487.
43. Paolisso G, Gambardella A, Verza M, D'Amore A, Sgambato S, Varrichio M: ACE inhibition improves insulin sensitivity in age insulin resistant hypertensive patients. J Hum Hypertens 1992;6:175-179.
44. UK Prospective Diabetes Study Group: Effect of intensive blood glucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865.
45. Wing RR, Koeske R, Epstein LH, et al: Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med 1987;147:1749-1753.
46. Dattilo AM, Kris-Etherton PM: Effects of weight reduction on blood lipids and lipoproteins: a metanalysis. Am J Clin Nutr 1992;56:320-328.
47. Lean ME, Powrie JK, Anderson AS, Garthwaite PH: Obesity weight loss and prognosis in type 2 diabetes. Diabetes Med 1990;7:228-233.
48. Williamson DF, Thompson TJ, Thun M, Flanders D, Pamuk E, Byers T: Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000;23:1499-1504.
49. St Jeor ST, Howard BV, Prewitt TE, Bovee V, Bazzarre T, Eckel RH: Dietary protein and weight reduction: A statement for healthcare professionals from the Nutrition Committee of the Council on Nutrition, Physical Activity, and Metabolism of the American Heart Association. Circulation 2001;104:1869-1874.
50. Hollander PA, Elbein SC, Hirsch IB, et al: Role of orlistat in the treatment of obese patients with type 2 diabetes: A 1-year randomised double blind study. Diabetes Care 1998;21:1288-1294.
51. Drent ML, van der Veen EA: Lipase inhibition: A novel concept in the treatment of obesity. Int J Obes Relat Metab Disord 1993;17:241-244.
52. Drent ML, Larsson I, William-Olssen T, et al: Orlistat (RO18-0647), a lipase inhibitor, in the treatment of human obesity: A multiple dose study. Int J Obes Relat Metab Disord 1995;19:221-226.
53. Buckett WR, Thomas PC, Luscombe GP: The pharmacology of sibutramine hydrochloride, a new anti-depressant which induces rapid noradrenergic down-regulation. Prog Neuropsychopharmacol Biol Psychiatry 1988;12:575-584.
54. Lean ME: Sibutramine: A review of clinical efficacy. Int J Obes Relat Disord 1997;21(suppl):30-36.
55. Bray GA, Ryan DH, Gordon D, Heidingsfelder S, Cerise F, Wilson K: A double-blind randomised placebo-controlled trial of sibutramine. Obes Res 1996;4:263-270.
56. Weintraub M, Rubio A, Golik A, Bryne L: Sibutramine in weight control: A dose-ranging efficacy study. Clin Pharmacol Ther 1991;50:330-337.
57. Bray GA, Blackburn GL, Ferguson JM, Greenway FI, Jain AK, Mendel CM, Mendels J, Ryan DH, Schwartz SL, Scheinbaum ML, Seaton TB: Sibutramine produces dose related weight loss. Obes Res 1999;7:189-198.
58. Griffiths J, Brynes AE, Frost G: Sibutramine in the treatment of overweight non-insulin dependent diabetics (abstract). Int J Obes 1995;19(suppl 2):144.
59. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
60. UK Prospective Diabetes Study Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
61. Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
62. Tuomilehto J, Lindstrom J, Eriksson JG, et al: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-1350.
63. Sjöstrom L: The natural history of massive obesity. Obes Res 1995;3:317.
64. WHO: Obesity: Preventing and Managing the Global Epidemic. Geneva, WHO, 1998, WHO/NUT/NCD/98.1.